Search PubMed⌕ Search

Biomedical subjects

D C Murray

Publications and source records attributed to D C Murray.

At least 37 records · Page 2Linked to original sources

Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease.

A cohort of 432 ESRD (261 hemodialysis and 171 peritoneal dialysis) patients was followed up prospectively for an average of 41 months. Baseline and annual demographic, clinical, and echocardiographic assessments were performed, as well as serial clinical and laboratory tests measured monthly while patients were on dialysis therapy. Among hemodialysis patients, after adjustment was made for age, diabetes, and ischemic heart disease, as well as hemoglobin and blood pressure levels measured serially, a 10-g/L fall in mean serum albumin level was independently associated with the the development of de novo (relative risk [RR], 2.22; P = 0.001) and recurrent cardiac failure (RR, 3.84; P = 0.003), de novo (RR, 5.29; P = 0.001) and recurrent ischemic heart disease (RR, 4.24; P = 0.005), cardiac mortality (RR, 5.60; P = 0.001), and overall mortality (RR, 4.33; P < 0.001). Among peritoneal dialysis patients, a 10-g/L fall in mean serum albumin level was independently associated with the progression of left ventricular dilation as seen on follow-up echocardiography (beta, 13.4 mL/m2; P = 0.014), the development of de novo cardiac failure (RR, 4.16; P = 0.003), and overall mortality (RR, 2.06; P < 0.001). Hypoalbuminemia, a major adverse prognostic factor in dialysis patients, is strongly associated with cardiac disease.

Adult↗

Outcome and risk factors for left ventricular disorders in chronic uraemia.

BACKGROUND: Left ventricular disease occurs frequently in dialysis patients. It may be manifest as concentric LV hypertrophy, LV dilatation with or without LV hypertrophy, or systolic dysfunction. Little is known concerning the clinical outcome and risk factors for these disorders. METHODS: A cohort of 432 end-stage renal disease patients who survived at least 6 months had an echocardiogram on initiation of dialysis therapy. Clinical, laboratory and echocardiographic data was obtained annually during follow-up. RESULTS: On initiation of ESRD therapy 16% of patients had systolic dysfunction, 41% concentric LV hypertrophy, 28% LV dilatation, and only 16% had normal echocardiograms. Median time to development of heart failure was 19 months in patients with systolic dysfunction, 38 months in concentric LV hypertrophy and 38 months in LV dilatation. The relative risks of heart failure in the three groups were significantly worse than in the normal group, after adjusting for age, diabetes and ischaemic heart disease. Median survival was 38 months in systolic dysfunction, 48 months in concentric hypertrophy, 56 months in LV dilatation, and >66 months in the normal group. Two hundred and seventy-five patients had a follow-up echocardiogram 17 months after starting dialysis therapy together with serial measurement of potential risk factors prior to the echocardiogram. On follow-up echocardiogram the degree of concentric LV hypertrophy was independently related to hypertension while on dialysis, older age, and anaemia while on dialysis; the degree of LV dilatation was related to ischaemic heart disease, anaemia, hypertension and hypoalbuminemia while on dialysis; the degree of systolic dysfunction was associated with ischaemic heart disease and anaemia during follow-up. CONCLUSIONS: Manifestations of left ventricular disease are frequent and persistent in chronic uraemia, and are associated with high risks of heart failure and death. Potentially reversible risk factors include anaemia, hypertension, hypoalbuminaemia and ischaemic heart disease.

Adult↗

Impact of renal transplantation on uremic cardiomyopathy.

In chronic uremia, cardiomyopathy manifests itself as systolic dysfunction, concentric left ventricular (LV) hypertrophy, or LV dilatation. To determine the impact of renal transplantation on uremic cardiomyopathy, all dialysis patients participating in a long-term cohort study who received a successful renal transplant were followed with echocardiography. The transplanted group comprised 102 of 433 (24%) endstage renal disease (ESRD) patients. They were significantly younger and, on starting ESRD therapy, had significantly less ischemic heart disease and cardiac failure than the overall ESRD cohort. During followup, ischemic heart disease developed in only 1 patient and none experienced cardiac failure. In the 12% (n = 12) of patients with systolic dysfunction before renal transplant, fractional shortening normalized in all patients, increasing from 21.5 +/- 4.6% to 33.5 +/- 5.6% after transplantation. In the 41% (n = 41) with concentric LV hypertrophy before transplantation, the LV mass index improved from 158 +/- 39 g/m2 to 132 +/- 39 g/m2. LV dilatation was present in 32% (n = 32) of patients before transplantation. After transplantation, LV volume fell from 116 +/- 3.1 ml/m2 to 89 +/- 21 ml/m2, and LV mass index in this group fell from 166 +/- 55 g/m2 to 135 +/- 37 g/m2. It was not possible to associate risk factors characteristic of the uremic state with the improvement in cardiac structure and function, although the fall in LV mass was significantly associated with fall in blood pressure. We conclude that correction of the uremic state by renal transplantation leads to normalization of LV contractility in systolic dysfunction, regression of hypertrophy in concentric LV hypertrophy, and improvement of cavity volume in LV dilatation. The degree of improvement suggests that dialysis patients with uremic cardiomyopathy would benefit from renal transplantation.

Adult↗

Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.

End-stage renal disease (ESRD) patients have a high cardiovascular mortality rate. Precise estimates of the prevalence, risk factors and prognosis of different manifestations of cardiac disease are unavailable. In this study a prospective cohort of 433 ESRD patients was followed from the start of ESRD therapy for a mean of 41 months. Baseline clinical assessment and echocardiography were performed on all patients. The major outcome measure was death while on dialysis therapy. Clinical manifestations of cardiovascular disease were highly prevalent at the start of ESRD therapy: 14% had coronary artery disease, 19% angina pectoris, 31% cardiac failure, 7% dysrhythmia and 8% peripheral vascular disease. On echocardiography 15% had systolic dysfunction, 32% left ventricular dilatation and 74% left ventricular hypertrophy. The overall median survival time was 50 months. Age, diabetes mellitus, cardiac failure, peripheral vascular disease and systolic dysfunction independently predicted death in all time frames. Coronary artery disease was associated with a worse prognosis in patients with cardiac failure at baseline. High left ventricular cavity volume and mass index were independently associated with death after two years. The independent associations of the different echocardiographic abnormalities were: systolic dysfunction-older age and coronary artery disease; left ventricular dilatation-male gender, anemia, hypocalcemia and hyperphosphatemia; left ventricular hypertrophy-older age, female gender, wide arterial pulse pressure, low blood urea and hypoalbuminemia. We conclude that clinical and echocardiographic cardiovascular disease are already present in a very high proportion of patients starting ESRD therapy and are independent mortality factors.

Cohort Studies↗

The prognostic importance of left ventricular geometry in uremic cardiomyopathy.

The objective of this study was to determine the effect of left ventricular (LV) mass, volume, and mass-to-volume ratio on mortality in chronic dialysis patients. The Design was a multicenter, prospective inception cohort study with a median follow-up of 41 months. The Setting was three university-affiliated nephrology units. A total of 433 patients who (1) survived > 6 months from the start of ESRD therapy and (2) had a technically satisfactory baseline echocardiogram were studied. Measurements included a baseline clinical, laboratory and echocardiographic assessment. LV hypertrophy was present in 74% and LV dilation was present in 36% of patients. In patients with normal cavity volume (< or = 90 mL/m2) and normal systolic function, high LV mass index (> 120 g/m2) and mass-to-volume ratios (> 2.2 g/mL) were independently associated with late mortality (> 2 yr after starting dialysis therapy). After adjusting for baseline age, diabetes, and ischemic heart disease, the relative risk for the former was 3.29 and for the latter was 2.24. Cavity volume was of no prognostic significance in this group. In patients with LV dilation and normal systolic function, high cavity volume (> 120 mL/m2) and low mass-to-volume ratio (< 1.8 mL/m2) were independently associated with late mortality, the relative risk in the former being 17.14 and the latter being 4.27. LV mass index was of no prognostic significance in this group. The baseline echocardiographic classification, based on LV mass and cavity volume, was the strongest predictor of late mortality, after adjusting for age, gender, diabetes mellitus, coronary artery disease, angina pectoris, chronic hypertension, and hemoglobin and serum albumin levels.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗

Photon beam convolution using polyenergetic energy deposition kernels.

In photon beam convolution calculations where polyenergetic energy deposition kernels (EDKS) are used, the primary photon energy spectrum should be correctly accounted for in Monte Carlo generation of EDKS. This requires the probability of interaction, determined by the linear attenuation coefficient, mu, to be taken into account when primary photon interactions are forced to occur at the EDK origin. The use of primary and scattered EDKS generated with a fixed photon spectrum can give rise to an error in the dose calculation due to neglecting the effects of beam hardening with depth. The proportion of primary photon energy that is transferred to secondary electrons increases with depth of interaction, due to the increase in the ratio mu ab/mu as the beam hardens. Convolution depth-dose curves calculated using polyenergetic EDKS generated for the primary photon spectra which exist at depths of 0, 20 and 40 cm in water, show a fall-off which is too steep when compared with EGS4 Monte Carlo results. A beam hardening correction factor applied to primary and scattered 0 cm EDKS, based on the ratio of kerma to terma at each depth, gives primary, scattered and total dose in good agreement with Monte Carlo results.

Algorithms↗

Beam hardening of 10 MV radiotherapy x-rays: analysis using a convolution/superposition method.

Total and primary polyenergetic dose spread arrays (PDSA) have been generated for a high energy 10 MV radiotherapy photon beam using the electron gamma shower (EGS) Monte Carlo code. By considering the attenuation of fluence per energy interval, PDSA have been produced at radiological depths of 0 cm (the surface PDSA) and 40 cm (the beam hardened PDSA). By comparing primary PDSA produced at these different depths, the effect of beam hardening on the PDSA has been quantified. Calculations show that the mean electron range due to the surface primary PDSA is 6.67 mm and the mean electron range of the beam hardened primary PDSA is 8.24 mm. In comparison, a 3 MeV primary monoenergetic dose spread array (MDSA) has a much smaller mean electron range of 4.81 mm. A radiotherapy x-ray beam computation method is introduced which involves a single superposition of the surface generated PDSA or beam hardened PDSA with a polyenergetic TERMA. The mean percentage difference between depth-dose curves obtained using super-position of surface and beam hardened PDSA is only 0.1%. The mean percentage difference from experimental data for these superposition curves is 2.8% down to 40 cm in a homogeneous phantom. The superposition process is shown to be forgiving to spectral differences when calculating the PDSA, but sensitive to the incident photon energy spectrum used to calculate the TERMA.

Biophysical Phenomena↗

The production of body analogs for use in radiation physics.

Bone, muscle and lung analog materials have been produced in-house, and dosimetry phantoms have been produced. A method using computed tomography (CT) has been developed to check that the analogs produced match the radiation properties of body tissues. The relative electron densities and ratio of electron cross sections are calculated from elemental compositions of the analogs. Using these data the theoretical CT numbers are calculated and these numbers are compared with experimental CT numbers for the analogs produced. The experimental CT numbers are found by scanning the samples on a Siemens DRH CT scanner. Results show the maximum difference between theoretical and experimental CT numbers for the analogs is 18 Hounsfield units, which relates to a delta NCT of less than 1%. Comparison of analog CT numbers with CT numbers for the related patient tissues also shows a close match.

Body Composition↗

Superposition dose calculation in lung for 10MV photons.

Currently available radiotherapy treatment planning systems employ scatter function models such as ETAR and Batho dSAR for dose calculation. Errors using these models for high energy photon irradiation occur in and beyond lung tissue for small fields. For larger fields, central axis dose is correctly predicted but penumbral broadening in lung is underestimated. The major source of error is the assumption that lateral electronic equilibrium is always established. A superposition algorithm has been developed for 10MV photons which calculates the dose by convolving the TERMA (Total Energy Released per unit MAss by primary photons) with a dose spread array formed using the EGS4 Monte Carlo code. TERMA and dose spread arrays are both generated using a 10 component photon energy spectrum. Dose in inhomogeneous media is calculated using dose spread arrays generated for different density media and by scaling dose spread arrays according to density variations. This method ensures that electronic disequilibrium is modelled in situations where it exists. Superposition results in a lung phantom for a 5 x 5 cm field agree with EGS4 Monte Carlo results to within 2% for p = 0.20 gcm-3 and p = 0.30 gcm-3 lung. Profiles generated by superposition for a 10 x 10 cm field at mid-lung and compared with film measurements show that penumbral broadening in low density material is also correctly predicted.

Algorithms↗

3-D superposition for radiotherapy treatment planning using fast Fourier transforms.

Currently used radiotherapy treatment planning algorithms based on effective path length or scatter function methods do not model electron ranging from photon interaction sites. The superposition (or convolution) technique does model this effect, which is especially important at higher (linear accelerator) energies since the electron range is significant. Another advantage of this method is that it is conceptually simple and models the physical processes directly, rather than using empirically derived methods. A major disadvantage of superposition lies in the large amount of computer time required to generate a plan, especially in three dimensions. To help solve this problem, superposition using an invariant dose spread array (kernel) can be achieved by performing a convolution in Fourier space using fast Fourier transforms (FFTs). A method for 3 dimensional calculation of dose using FFTs is presented. Dose spread arrays are calculated using the EGS Monte Carlo code, and convolved with the TERMA (total energy released per unit mass). In both cases a 10 MV nominal beam energy is modelled by a 10 component spectrum, which is compared to the result obtained using monochromatic energy only (3.0 MeV at the surface). The FFT technique is shown to be significantly faster than standard convolution for medium to large TERMA and dose spread array sizes. The method is shown to be highly accurate for small fields in homogeneous media. For larger fields the central axis depth dose is accurate but the profile shape in the penumbral region becomes slightly distorted. This is because photons incident near the beam edges are not parallel to the cartesian coordinate system used as the convolution framework. However, this effect is sufficiently small to indicate that the convolution method is suitable for use in routine treatment planning.

Fourier Analysis↗

Modelling polychromatic high energy photon beams by superposition.

A unified three dimensional superposition approach to dose calculations used in treatment planning of polychromatic high energy photon beams in radiotherapy is developed. The approach we have used involves computing the dose at all points in a medium by superposing the dose spread array (DSA) from the interaction of a photon at a point in the medium with an array of data representing the TERMA (photon fluence times the photon energy) at points in the beam. The polychromatic nature of the beam is accounted for by modelling the beam as having ten spectral components. A "polychromatic dose spread array" (PDSA) for an interaction from a beam with this spectrum was derived. The TERMA array is calculated from a weighted average of the TERMA arrays for the ten photon energies to give a "polychromatic TERMA array". Thus the method accounts for the effect of beam hardening of the TERMA. But it does not account for the effect of beam hardening on the PDSA since a single PDSA (usually for the spectrum at the surface of the medium) is used at all depths. However, by considering measured and calculated beam central axis data, this model is shown to be adequate for computing depth doses for beams in a homogeneous medium penetrating to extreme radiological depths. A computation time advantage is gained because only one superposition per beam is required.

Humans↗